Analysis

Ovid Therapeutics Inc. (OVID) Stock Analysis

Ovid Therapeutics Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to OVID.

websiteOVID/analysis/OVID

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to OVID.

Stock profile

Ticker

OVID

Asset type

Stock

Market cap

$423.7M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Ovid Therapeutics Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • OVID primary listing
  • 1OT
  • A2DQ8S

Latest Ovid Therapeutics Inc. news

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 ...

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Ye...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile

Research sections

Valuation

Review valuation context for Ovid Therapeutics Inc..

Future growth

Review future growth context for Ovid Therapeutics Inc..

Past performance

Review past performance context for Ovid Therapeutics Inc..

Financial health

Review financial health context for Ovid Therapeutics Inc..

Dividend

Review dividend context for Ovid Therapeutics Inc..

Management

Review management context for Ovid Therapeutics Inc..

Ownership

Review ownership context for Ovid Therapeutics Inc..

Other information

Review other information context for Ovid Therapeutics Inc..

Community

Review community context for Ovid Therapeutics Inc..